Factors affecting the efficacy and safety of phosphodiesterase 5 inhibitor and placebo in treatment for lower urinary tract symptoms: meta-analysis and meta-regression
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Sun, Hwa Yeon | - |
dc.contributor.author | Lee, Bora | - |
dc.contributor.author | Kim, Jae Heon | - |
dc.date.accessioned | 2021-06-18T07:43:50Z | - |
dc.date.available | 2021-06-18T07:43:50Z | - |
dc.date.issued | 2018-01 | - |
dc.identifier.issn | 0301-1623 | - |
dc.identifier.issn | 1573-2584 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/45360 | - |
dc.description.abstract | We aimed to investigate the real benefit and safety of phosphodiesterase 5 inhibitor (PDE 5I) for benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS) by determining the affecting factors and to overcome the previous meta-analysis studies. We conducted a systematic review of improvements in LUTS using International Prostate Symptom Score (IPSS), voiding subscore of IPSS (voiding IPSS), storage subscore of IPSS (storage IPSS), quality of life (QoL), maximal urinary flow rate (Qmax), and post-voided residual volume (PVR), and also investigated adverse events and relevant withdrawal rate. Final included studies were 28 studies with 19,820 subjects (9800 treatment group and 10,020 control group). The overall weighted mean differences of total IPSS, voiding IPSS, storage IPSS, and QoL showed significant improvement. Single placebo group showed significant improvement in all outcomes except PVR. The weighted prevalence of overall withdrawal rate and adverse event-specific withdrawal rate was 10 and 3%, respectively. Meta-regression showed that baseline IPSS, dosage of PDE 5I, and country affect clinical improvement compared with placebo. This study clarifies the efficacy of PDE 5I on treatment of BPH/LUTS as an initial treatment strategy. However, baseline IPSS, dosage of PDE 5I and country affected the clinical improvement. Moreover, adverse event-specific withdrawal rate was not as high as suspected based on the overall withdrawal rate. | - |
dc.format.extent | 13 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | SPRINGER | - |
dc.title | Factors affecting the efficacy and safety of phosphodiesterase 5 inhibitor and placebo in treatment for lower urinary tract symptoms: meta-analysis and meta-regression | - |
dc.type | Article | - |
dc.identifier.doi | 10.1007/s11255-017-1743-3 | - |
dc.identifier.bibliographicCitation | INTERNATIONAL UROLOGY AND NEPHROLOGY, v.50, no.1, pp 35 - 47 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000419704800007 | - |
dc.identifier.scopusid | 2-s2.0-85033461908 | - |
dc.citation.endPage | 47 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 35 | - |
dc.citation.title | INTERNATIONAL UROLOGY AND NEPHROLOGY | - |
dc.citation.volume | 50 | - |
dc.type.docType | Article | - |
dc.publisher.location | 네델란드 | - |
dc.subject.keywordAuthor | Prostatic hyperplasia | - |
dc.subject.keywordAuthor | Phosphodiesterase 5 inhibitor | - |
dc.subject.keywordAuthor | Lower urinary tract symptoms | - |
dc.subject.keywordAuthor | Meta-analysis | - |
dc.subject.keywordAuthor | Placebo | - |
dc.subject.keywordPlus | BENIGN PROSTATIC HYPERPLASIA | - |
dc.subject.keywordPlus | TAMSULOSIN 0.2 MG | - |
dc.subject.keywordPlus | 1ST-LINE TREATMENT | - |
dc.subject.keywordPlus | CLINICAL-TRIALS | - |
dc.subject.keywordPlus | ALPHA-BLOCKERS | - |
dc.subject.keywordPlus | SECONDARY | - |
dc.subject.keywordPlus | MONOTHERAPY | - |
dc.subject.keywordPlus | TADALAFIL | - |
dc.subject.keywordPlus | UROLOGY | - |
dc.subject.keywordPlus | UPDATE | - |
dc.relation.journalResearchArea | Urology & Nephrology | - |
dc.relation.journalWebOfScienceCategory | Urology & Nephrology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.